{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:34:16Z","timestamp":1792809256818,"version":"4.5.0"},"reference-count":210,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.lfs.2023.122331","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T02:44:45Z","timestamp":1701917085000},"page":"122331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Vaccine development: Current trends and technologies"],"prefix":"10.1016","volume":"336","author":[{"given":"Renu","family":"Poria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupak","family":"Nagraik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashika","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen Kumar","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Salik","family":"Noorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Kaushal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagun","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2023.122331_bb0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0010","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0020","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0025","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0030","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","article-title":"Immunologic basis of vaccine vectors","volume":"33","author":"Liu","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2023.122331_bb0035","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Tagliabue","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0040","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/302490a0","article-title":"Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen","volume":"302","author":"Smith","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2023.122331_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/311067a0","article-title":"Live recombinant vaccinia virus protects chimpanzees against hepatitis B","volume":"311","author":"Moss","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2023.122331_bb0050","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1128\/jvi.67.4.2370-2375.1993","article-title":"Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL","volume":"67","author":"Tartaglia","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2023.122331_bb0055","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1637\/10540-032613-Reg.1","article-title":"Protection and antibody response caused by Turkey herpesvirus vector Newcastle disease vaccine","volume":"57","author":"Esaki","year":"2013","journal-title":"Avian Dis."},{"key":"10.1016\/j.lfs.2023.122331_bb0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.lfs.2023.122331_bb0065","series-title":"Recombinant Tri-segmented Pichinde Virus as a Novel Live Viral Vaccine Platform","first-page":"169","author":"Dhanwani","year":"2017"},{"key":"10.1016\/j.lfs.2023.122331_bb0070","doi-asserted-by":"crossref","first-page":"10200","DOI":"10.1128\/JVI.79.16.10200-10209.2005","article-title":"Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies","volume":"79","author":"Peng","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2023.122331_bb0075","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0080","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.virol.2005.09.020","article-title":"Replication-defective viruses as vaccines and vaccine vectors","volume":"344","author":"Dudek","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.lfs.2023.122331_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2018.1419067","article-title":"Single-cycle adenovirus vectors in the current vaccine landscape","author":"Barry","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem","year":"2011","journal-title":"J. Global Infect. Dis."},{"key":"10.1016\/j.lfs.2023.122331_bb0095","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.lfs.2023.122331_bb0100","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2023.122331_bb0105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.lfs.2023.122331_bb0120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/14760584.6.3.381","article-title":"Virus-like particles: flexible platforms for vaccine development","volume":"6","author":"Chackerian","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0130","author":"GlaxoSmithKline"},{"key":"10.1016\/j.lfs.2023.122331_bb0140","author":"DailyMed"},{"key":"10.1016\/j.lfs.2023.122331_bb0145","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0150","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0155","article-title":"Influenza virus-like particles containing M2 induce broadly cross protective immunity","volume":"6","author":"Song","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2023.122331_bb0160","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1016\/j.vaccine.2009.03.043","article-title":"Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease","volume":"27","author":"El-Attar","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1743-422X-8-3","article-title":"Prime immunization with rotavirus VLP 2\/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice","volume":"8","author":"Zhou","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.lfs.2023.122331_bb0170","series-title":"Subunit Protein Vaccine Delivery System for Tuberculosis Based on Hepatitis B Virus Core VLP (HBc-VLP) Particles","first-page":"377","author":"Dhanasooraj","year":"2016"},{"key":"10.1016\/j.lfs.2023.122331_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005608","article-title":"Zika virus-like particle (VLP) based vaccine","volume":"11","author":"Boigard","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.lfs.2023.122331_bb0180","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/QAI.0b013e31820b844e","article-title":"CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells","volume":"56","author":"Franco","year":"2011","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.lfs.2023.122331_bb0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-8518-8-7","article-title":"HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice","volume":"8","author":"Pillay","year":"2010","journal-title":"J. Immune Based Ther. Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.lfs.2023.122331_bb0195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/polym10010031","article-title":"Polymer-based nanomaterials and applications for vaccines and drugs","volume":"10","author":"Han","year":"2018","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.lfs.2023.122331_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle vaccines against infectious diseases","volume":"9","author":"Pati","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0205","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.7150\/thno.20745","article-title":"Rational design of polymeric hybrid micelles to overcome lymphatic and intracellular delivery barriers in cancer immunotherapy","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.lfs.2023.122331_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00022","article-title":"Nanoparticle-based vaccines against respiratory viruses","volume":"10","author":"Al-Halifa","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0215","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.3390\/ijms19113605","article-title":"DNA vaccines\u2014how far from clinical use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2023.122331_bb0220","doi-asserted-by":"crossref","first-page":"26","DOI":"10.11599\/germs.2013.1034","article-title":"DNA vaccines: roles against diseases","volume":"3","author":"Khan","year":"2013","journal-title":"GERMS"},{"key":"10.1016\/j.lfs.2023.122331_bb0225","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.vaccine.2005.08.076","article-title":"DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime\/protein boost strategy","volume":"24","author":"Kennedy","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0230","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"Li","year":"2012","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.lfs.2023.122331_bb0235","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00263-17","article-title":"DNA priming increases frequency of T-cell responses to a vesicular stomatitis virus HIV vaccine with specific enhancement of CD8 + T-cell responses by interleukin-12 plasmid DNA","volume":"24","author":"Li","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13331-1","article-title":"Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial","volume":"7","author":"Haidari","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122331_bb0245","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2017-0151","article-title":"Latest development on RNA-based drugs and vaccines","volume":"4","author":"Lundstrom","year":"2018","journal-title":"Futur. Sci. OA"},{"key":"10.1016\/j.lfs.2023.122331_bb0250","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.biomaterials.2017.09.033","article-title":"Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination","volume":"150","author":"Uchida","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2023.122331_bb0255","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2217\/nnm-2016-0102","article-title":"Post isolation modification of exosomes for nanomedicine applications","volume":"11","author":"Hood","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.lfs.2023.122331_bb0260","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2013.07.011","article-title":"Turning tumors into vaccines: co-opting the innate immune system","volume":"39","author":"van den Boorn","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2023.122331_bb0265","doi-asserted-by":"crossref","first-page":"29007","DOI":"10.18632\/oncotarget.25626","article-title":"Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment","volume":"9","author":"Elion","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2023.122331_bb0270","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2023.122331_bb0275","series-title":"Self-replicating RNA Vaccine Delivery to Dendritic Cells","first-page":"37","author":"D\u00e9moulins","year":"2017"},{"key":"10.1016\/j.lfs.2023.122331_bb0280","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.omtn.2018.04.019","article-title":"Self-amplifying replicon RNA delivery to dendritic cells by cationic lipids","volume":"12","author":"Englezou","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.lfs.2023.122331_bb0285","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2023.122331_bb0290","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2023.122331_bb0295","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2023.122331_bb0300","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.gt.3302213","article-title":"Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation","volume":"11","author":"Wang","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.lfs.2023.122331_bb0305","doi-asserted-by":"crossref","first-page":"79","DOI":"10.21775\/cimb.022.079","article-title":"DNA vaccines: regulatory considerations and safety aspects","author":"Myhr","year":"2017","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.lfs.2023.122331_bb0310","series-title":"Introduction to RNA Vaccines","first-page":"1","author":"Kramps","year":"2017"},{"key":"10.1016\/j.lfs.2023.122331_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003001","article-title":"Vaccines: from empirical development to rational design","volume":"8","author":"Rueckert","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2023.122331_bb0320","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1021\/cb300487u","article-title":"Rational epitope design for protein targeting","volume":"8","author":"Peri","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.lfs.2023.122331_bb0325","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/intimm\/dxx077","article-title":"Toward rational antibody design: recent advancements in molecular dynamics simulations","volume":"30","author":"Yamashita","year":"2018","journal-title":"Int. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0330","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coviro.2015.03.013","article-title":"Computational tools for epitope vaccine design and evaluation","volume":"11","author":"He","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.lfs.2023.122331_bb0335","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1084\/jem.20151960","article-title":"Reverse vaccinology 2.0: human immunology instructs vaccine antigen design","volume":"213","author":"Rappuoli","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0340","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science (80-. )"},{"key":"10.1016\/j.lfs.2023.122331_bb0345","series-title":"Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine","first-page":"73","author":"Zhou","year":"2018"},{"key":"10.1016\/j.lfs.2023.122331_bb0350","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.2174\/15680266113136660187","article-title":"Structural vaccinology: a three-dimensional view for vaccine development","volume":"13","author":"Ferlenghi","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.lfs.2023.122331_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01194","article-title":"Mapping determinants of virus neutralization and viral escape for rational design of a hepatitis C virus vaccine","volume":"9","author":"Keck","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz6225","article-title":"Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines","volume":"6","author":"He","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.lfs.2023.122331_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02247","article-title":"Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention","volume":"10","author":"Aiello","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0370","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10522-014-9514-3","article-title":"Innate immunesenescence: underlying mechanisms and clinical relevance","volume":"16","author":"Hazeldine","year":"2015","journal-title":"Biogerontology"},{"key":"10.1016\/j.lfs.2023.122331_bb0375","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1189\/jlb.5MR0315-104R","article-title":"Paradoxical changes in innate immunity in aging: recent progress and new directions","volume":"98","author":"Montgomery","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.lfs.2023.122331_bb0380","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1039\/C6CS00858E","article-title":"Principles of mucin structure: implications for the rational design of cancer vaccines derived from MUC1-glycopeptides","volume":"46","author":"Mart\u00ednez-S\u00e1ez","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.lfs.2023.122331_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: from whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2023.122331_bb0390","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2017.05.014","article-title":"Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming","volume":"258","author":"Zupan\u010di\u010d","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2023.122331_bb0395","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acschembio.7b00958","article-title":"Rational-differential design of highly specific glycomimetic ligands: targeting DC-SIGN and excluding Langerin recognition","volume":"13","author":"Porkolab","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.lfs.2023.122331_bb0400","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/21645515.2015.1094595","article-title":"Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production","volume":"12","author":"Oyarz\u00fan","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.lfs.2023.122331_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/156241","article-title":"Structural and computational biology in the design of immunogenic vaccine antigens","volume":"2015","author":"Liljeroos","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.lfs.2023.122331_bb0410","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nri.2017.54","article-title":"Unique aspects of the perinatal immune system","volume":"17","author":"Zhang","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0415","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.immuni.2012.10.014","article-title":"Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly","volume":"37","author":"Kollmann","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2023.122331_bb0420","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.4049\/jimmunol.162.6.3342","article-title":"B cell maintenance in aged mice reflects both increased B cell longevity and decreased B cell generation","volume":"162","author":"Kline","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0425","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4049\/jimmunol.158.4.1598","article-title":"Development of B cells in aged mice: decline in the ability of pro-B cells to respond to IL-7 but not to other growth factors","volume":"158","author":"Stephan","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0430","doi-asserted-by":"crossref","DOI":"10.1038\/srep30842","article-title":"The aged lymphoid tissue environment fails to support na\u00efve T cell homeostasis","volume":"6","author":"Becklund","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122331_bb0435","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2004-07-2599","article-title":"The origins of age-related proinflammatory state","volume":"105","author":"Ferrucci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2023.122331_bb0440","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.febslet.2005.02.055","article-title":"Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity","volume":"579","author":"De Martinis","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.lfs.2023.122331_bb0445","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1365-2567.2002.01381.x","article-title":"Influence of ageing on Langerhans cell migration in mice: identification of a putative deficiency of epidermal interleukin-1beta","volume":"105","author":"Cumberbatch","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.lfs.2023.122331_bb0450","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1189\/jlb.0809542","article-title":"Leukocyte function in the aging immune system","volume":"87","author":"Desai","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.lfs.2023.122331_bb0455","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2249.2008.03658.x","article-title":"Ageing is associated with diminished apoptotic cell clearance in vivo","volume":"152","author":"Aprahamian","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0460","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.0105-2896.2005.00276.x","article-title":"Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. John Cambier","volume":"205","author":"Cambier","year":"2005","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.lfs.2023.122331_bb0465","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.4049\/jimmunol.1301721","article-title":"Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans","volume":"192","author":"Wertheimer","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0470","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.smim.2012.04.004","article-title":"B cell maintenance and function in aging","volume":"24","author":"Kogut","year":"2012","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0475","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.lfs.2023.122331_bb0480","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.imlet.2004.04.015","article-title":"Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications","volume":"94","author":"Rutella","year":"2004","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.lfs.2023.122331_bb0485","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4049\/jimmunol.0802046","article-title":"Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients","volume":"183","author":"Luther","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0490","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.4049\/jimmunol.0801155","article-title":"TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program","volume":"183","author":"Chamorro","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0495","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: from 1920 to 2015 and beyond","volume":"3","author":"Pasquale","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0500","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1172\/JCI81083","article-title":"Beyond antigens and adjuvants: formulating future vaccines","volume":"126","author":"Moyer","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2023.122331_bb0505","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1074-7613(01)00103-0","article-title":"Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets","volume":"14","author":"Grogan","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2023.122331_bb0510","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0515","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-3083.2008.02225.x","article-title":"IC31\u00ae, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice","volume":"69","author":"Olafsdottir","year":"2009","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0520","doi-asserted-by":"crossref","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122331_bb0525","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41541-017-0020-x","article-title":"DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections","volume":"2","author":"Elliott","year":"2017","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0530","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.4049\/jimmunol.163.11.6306","article-title":"Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus","volume":"163","author":"Vallin","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0535","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.imlet.2012.01.003","article-title":"Selective binding of anti-DNA antibodies to native dsDNA fragments of differing sequence","volume":"143","author":"Uccellini","year":"2012","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.lfs.2023.122331_bb0540","doi-asserted-by":"crossref","first-page":"9258","DOI":"10.1073\/pnas.0500132102","article-title":"The evolution of human anti-double-stranded DNA autoantibodies","volume":"102","author":"Wellmann","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2023.122331_bb0545","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0550","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2010.03.027","article-title":"Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response","volume":"145","author":"Henriksen-Lacey","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2023.122331_bb0555","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"van Dissel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0560","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa0807381","article-title":"Efficacy of RTS,S\/AS01E vaccine against malaria in children 5 to 17 months of age","volume":"359","author":"Bejon","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0565","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1473-3099(10)70262-0","article-title":"Efficacy of RTS,S\/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5\u201317 months in Kenya and Tanzania: a randomised controlled trial","volume":"11","author":"Olotu","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.lfs.2023.122331_bb0570","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pervac.2011.05.006","article-title":"Vaccines of the future","volume":"1","author":"Stanberry","year":"2011","journal-title":"Perspect. Vaccinol."},{"key":"10.1016\/j.lfs.2023.122331_bb0575","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","article-title":"Use of defined TLR ligands as adjuvants within human vaccines","volume":"239","author":"Duthie","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.lfs.2023.122331_bb0580","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.4049\/jimmunol.0901296","article-title":"TLR-activated dendritic cells enhance the response of aged naive CD4 T cells via an IL-6\u2013dependent mechanism","volume":"185","author":"Jones","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0585","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1086\/428589","article-title":"Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections","volume":"191","author":"Gill","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.lfs.2023.122331_bb0590","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1128\/JVI.00743-08","article-title":"Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral","volume":"82","author":"Dimmock","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2023.122331_bb0595","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1080\/21645515.2016.1212785","article-title":"Biologics to treat substance use disorders: current status and new directions","volume":"12","author":"Pravetoni","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.lfs.2023.122331_bb0600","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/378727a0","article-title":"Suppression of psychoactive effects of cocaine by active immunization","volume":"378","author":"Carrera","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2023.122331_bb0605","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0264-410X(01)00425-X","article-title":"Human therapeutic cocaine vaccine: safety and immunogenicity","volume":"20","author":"Kosten","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0610","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.biopsych.2005.04.032","article-title":"Vaccine pharmacotherapy for the treatment of cocaine dependence","volume":"58","author":"Martell","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.lfs.2023.122331_bb0615","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/erv.13.13","article-title":"Therapeutic vaccines against tobacco addiction","volume":"12","author":"Fahim","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0620","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1016\/j.vaccine.2013.07.038","article-title":"Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food","volume":"31","author":"R\u00fcedi-Bettschen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0625","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40263-020-00722-8","article-title":"Preclinical evaluation of vaccines to treat opioid use disorders: how close are we to a clinically viable therapeutic?","volume":"34","author":"Townsend","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.lfs.2023.122331_bb0630","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/erv.11.60","article-title":"Review of diphtheria, tetanus and pertussis vaccines in clinical development","volume":"10","author":"Kitchin","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0635","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/acs.bioconjchem.7b00692","article-title":"Toxoid vaccination against bacterial infection using cell membrane-coated nanoparticles","volume":"29","author":"Angsantikul","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.lfs.2023.122331_bb0640","doi-asserted-by":"crossref","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","article-title":"Preclinical and clinical development of neoantigen vaccines","volume":"28","author":"Li","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2023.122331_bb0645","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13046-018-0751-1","article-title":"The perfect personalized cancer therapy: cancer vaccines against neoantigens","volume":"37","author":"Aurisicchio","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2019","key":"10.1016\/j.lfs.2023.122331_bb0650","doi-asserted-by":"crossref","first-page":"654","DOI":"10.12688\/f1000research.18693.1","article-title":"Strategies for developing and optimizing cancer vaccines","volume":"8","author":"Maeng","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.lfs.2023.122331_bb0655","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.4161\/21645515.2014.973317","article-title":"Antigen-specific vaccines for cancer treatment","volume":"10","author":"Tagliamonte","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.lfs.2023.122331_bb0660","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science (80-. )"},{"key":"10.1016\/j.lfs.2023.122331_bb0665","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/eji.200635910","article-title":"Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA","volume":"36","author":"Scheel","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0670","doi-asserted-by":"crossref","DOI":"10.1038\/srep22509","article-title":"Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours","volume":"6","author":"Bialkowski","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122331_bb0675","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","article-title":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study","volume":"3","author":"K\u00fcbler","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lfs.2023.122331_bb0680","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1023\/A:1020989709019","article-title":"In vivo characteristics of cationic liposomes as delivery vectors for gene therapy","volume":"19","author":"Audouy","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.lfs.2023.122331_bb0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","article-title":"Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics","volume":"203","author":"Lorenzer","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2023.122331_bb0690","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00262-005-0064-z","article-title":"Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor\/self antigen","volume":"55","author":"Hess","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2023.122331_bb0695","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/0022034518764416","article-title":"Engineering vaccines to reprogram immunity against head and neck cancer","volume":"97","author":"Tan","year":"2018","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.lfs.2023.122331_bb0700","article-title":"Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans","volume":"7","author":"Lu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2023.122331_bb0705","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(12)62166-7","article-title":"Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)","volume":"381","author":"Cho","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2023.122331_bb0710","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/1535-7163.MCT-16-0541","article-title":"Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA)","volume":"16","author":"Wagner","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2023.122331_bb0715","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0720","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","article-title":"A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients","volume":"24","author":"Wilgenhof","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2023.122331_bb0725","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2023.122331_bb0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/794528","article-title":"RNA-based vaccines in cancer immunotherapy","volume":"2015","author":"McNamara","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.lfs.2023.122331_bb0735","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1256527","article-title":"Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles","volume":"6","author":"Sayour","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lfs.2023.122331_bb0740","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ymthe.2017.11.009","article-title":"mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma","volume":"26","author":"Wang","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2023.122331_bb0745","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.lfs.2023.122331_bb0750","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00766","article-title":"Personalized dendritic cell vaccines\u2014recent breakthroughs and encouraging clinical results","volume":"10","author":"Mastelic-Gavillet","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0755","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14760584.2018.1455505","article-title":"Virus-like antigen display for cancer vaccine development, what is the potential?","volume":"17","author":"Sander","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0760","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2020.03.018","article-title":"Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)","volume":"132","author":"Singer","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lfs.2023.122331_bb0765","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/2326-6066.CIR-16-0283","article-title":"Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines","volume":"5","author":"Varypataki","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lfs.2023.122331_bb0770","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.nano.2017.12.011","article-title":"Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer","volume":"14","author":"Zupan\u010di\u010d","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0775","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0268","article-title":"Tumour virus vaccines: hepatitis B virus and human papillomavirus","volume":"372","author":"Stanley","year":"2017","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.lfs.2023.122331_bb0780","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10549-009-0666-9","article-title":"A virosomal formulated Her-2\/neu multi-peptide vaccine induces Her-2\/neu-specific immune responses in patients with metastatic breast cancer: a phase I study","volume":"119","author":"Wiedermann","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.lfs.2023.122331_bb0785","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1158\/1078-0432.CCR-16-0088","article-title":"Immunotherapy with a HER2-targeting Listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma","volume":"22","author":"Mason","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2023.122331_bb0790","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nnano.2015.292","article-title":"In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer","volume":"11","author":"Lizotte","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.lfs.2023.122331_bb0795","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.nano.2018.09.004","article-title":"Protein-based nanoparticles in cancer vaccine development","volume":"15","author":"Neek","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0800","author":"WHO EMRO"},{"key":"10.1016\/j.lfs.2023.122331_bb0805","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMoa1609462","article-title":"Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger","volume":"376","author":"Isanaka","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0810","author":"Fda"},{"key":"10.1016\/j.lfs.2023.122331_bb0815","article-title":"Emerging technologies for low-cost, rapid vaccine manufacture","author":"Kis","year":"2018","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.lfs.2023.122331_bb0820","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","article-title":"Universal influenza vaccines: shifting to better vaccines","volume":"34","author":"Berlanda Scorza","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0825","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1016\/j.vaccine.2017.04.085","article-title":"Rapid development of vaccines against emerging pathogens: the replication-deficient simian adenovirus platform technology","volume":"35","author":"Gilbert","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0830","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coviro.2016.01.007","article-title":"Selection of HIV vaccine candidates for concurrent testing in an efficacy trial","volume":"17","author":"Huang","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.lfs.2023.122331_bb0835","doi-asserted-by":"crossref","DOI":"10.1038\/srep20617","article-title":"Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122331_bb0840","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1080\/21645515.2017.1306615","article-title":"Vaccines for epidemic infections and the role of CEPI","volume":"13","author":"Plotkin","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.lfs.2023.122331_bb0845","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.vaccine.2016.10.080","article-title":"Policy making for vaccine use as a driver of vaccine innovation and development in the developed world","volume":"35","author":"Seib","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0850","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.chom.2019.04.013","article-title":"Preventing an antigenically disruptive mutation in egg-based H3N2 seasonal influenza vaccines by mutational incompatibility","volume":"25","author":"Wu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.lfs.2023.122331_bb0855","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.633776","article-title":"A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications","volume":"9","author":"Qin","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.lfs.2023.122331_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114000","article-title":"Messenger RNA-based vaccines: past, present, and future directions in the context of the COVID-19 pandemic","volume":"179","author":"Jain","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2023.122331_bb0865","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.inmuno.2012.08.002","article-title":"Virus-like particle-based vaccines for animal viral infections","volume":"32","author":"Crisci","year":"2013","journal-title":"Inmunolog\u00eda"},{"key":"10.1016\/j.lfs.2023.122331_bb0870","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/vaccines8030373","article-title":"Progress in the development of subunit vaccines against malaria","volume":"8","author":"Skwarczynski","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0875","doi-asserted-by":"crossref","first-page":"S957","DOI":"10.1093\/infdis\/jix464","article-title":"Zika virus vaccine development","volume":"216","author":"Morabito","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.lfs.2023.122331_bb0880","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3390\/cells9122673","article-title":"Recent advances in the development of protein- and peptide-based subunit vaccines against tuberculosis","volume":"9","author":"Bellini","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2023.122331_bb0885","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.1016\/j.vaccine.2018.10.072","article-title":"Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature","volume":"36","author":"Boigard","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2023.122331_bb0890","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus vaccine development: from SARS and MERS to COVID-19","volume":"27","author":"Li","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.lfs.2023.122331_bb0895","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape","volume":"23","author":"Mazur","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.lfs.2023.122331_bb0900","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","article-title":"The ClinicalTrials.gov results database \u2014 update and key issues","volume":"364","author":"Zarin","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0905","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0910","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40475-020-00201-6","article-title":"The SARS-CoV-2 vaccine pipeline: an overview","volume":"7","author":"Chen","year":"2020","journal-title":"Curr. Trop. Med. Rep."},{"key":"10.1016\/j.lfs.2023.122331_bb0915","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2023.122331_bb0920","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/d41586-020-00751-9","article-title":"Don\u2019t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees","volume":"579","author":"Jiang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2023.122331_bb0925","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/eji.202048663","article-title":"COVID-19 vaccines: knowing the unknown","volume":"50","author":"Lv","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0930","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19","volume":"20","author":"Iwasaki","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0935","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/S0140-6736(20)31354-4","article-title":"COVID-19 vaccines for all?","volume":"395","author":"Usher","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2023.122331_bb0940","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(20)30763-7","article-title":"Ensuring global access to COVID-19 vaccines","volume":"395","author":"Yamey","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2023.122331_bb0945","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging Concepts and technologies in vaccine development","volume":"11","author":"Brisse","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb0950","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0955","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2023.122331_bb0960","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0965","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41541-022-00590-x","article-title":"A phase I\/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine","volume":"7","author":"Low","year":"2022","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0970","article-title":"Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model","volume":"2","author":"Patel","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.lfs.2023.122331_bb0975","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2666-5247(21)00358-X","article-title":"Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults","volume":"3","author":"Ahn","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lfs.2023.122331_bb0980","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3390\/vaccines10091427","article-title":"Phase I study to assess the safety and immunogenicity of an intradermal COVID-19 DNA vaccine administered using a pyro-drive jet injector in healthy adults","volume":"10","author":"Nakagami","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.lfs.2023.122331_bb0985","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2023.122331_bb0990","first-page":"122","article-title":"An outline of contributing vaccine technologies for SARS CoV2 advancing in clinical and preclinical phase-trials, recent pat","volume":"16","author":"Naz","year":"2022","journal-title":"Biotechnology"},{"key":"10.1016\/j.lfs.2023.122331_bb0995","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01880","article-title":"The 2020 pandemic: current SARS-CoV-2 vaccine development","volume":"11","author":"Alturki","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb1000","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1122389","article-title":"Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-year follow-up: phase I and II clinical trial final result","volume":"14","author":"Jonny","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2023.122331_bb1005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7774\/cevr.2021.10.2.154","article-title":"Inside the story about the research and development of COVID-19 vaccines","volume":"10","author":"Patel","year":"2021","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.lfs.2023.122331_bb1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106054","article-title":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies","volume":"56","author":"Sharma","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2023.122331_bb1015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/08820139.2021.1904977","article-title":"Pharmaceutical aspects and clinical evaluation of COVID-19 vaccines","volume":"50","author":"Hofman","year":"2021","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.lfs.2023.122331_bb1020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2023.122331_bb1025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2023.122331_bb1030","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2023.122331_bb1035","article-title":"Covid-19: where are we on immunity and vaccines?","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.lfs.2023.122331_bb1040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2023.122331_bb1045","article-title":"Covid-19: Russia approves vaccine without large scale testing or published results","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.lfs.2023.122331_bb1050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/v13020317","article-title":"Viral vectors for COVID-19 vaccine development","volume":"13","author":"Lundstrom","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.lfs.2023.122331_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103811","article-title":"Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1\/2 randomised, double-blind, placebo-controlled, dose-ranging trial","volume":"75","author":"Vanhoutte","year":"2022","journal-title":"EBioMedicine"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523009669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523009669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:20:26Z","timestamp":1758403226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320523009669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":210,"alternative-id":["S0024320523009669"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122331","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine development: Current trends and technologies","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122331"}}